Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;38(10):1015-1027.
doi: 10.1016/j.healun.2019.08.003. Epub 2019 Aug 8.

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric lung and heart-lung transplantation report-2019; Focus theme: Donor and recipient size match

Don Hayes Jr  1 , Wida S Cherikh  1 , Daniel C Chambers  1 , Michael O Harhay  1 , Kiran K Khush  1 , Rebecca R Lehman  1 , Bruno Meiser  1 , Joseph W Rossano  1 , Eileen Hsich  1 , Luciano Potena  1 , Aparna Sadavarte  1 , Tajinder P Singh  1 , Andreas Zuckermann  1 , Josef Stehlik  2 ; International Society for Heart and Lung Transplantation  1
Affiliations

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric lung and heart-lung transplantation report-2019; Focus theme: Donor and recipient size match

Don Hayes Jr et al. J Heart Lung Transplant. 2019 Oct.
No abstract available

Keywords: Immunosuppression; Lung transplant; Organ donor; Rejection; Survival.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement

M.H, D.H, T.S, E.H, B.M, W.C, A.R, and A.S have no conflicts to report.

Figures

Figure 1
Figure 1
Recipient age distribution for pediatric lung transplants (transplants: January 1992–June 2018).
Figure 2
Figure 2
Number of centers reporting pediatric lung transplants by transplant year and pediatric center volume (transplants: 1988–2017).
Figure 3
Figure 3
Diagnosis distribution for pediatric lung transplants by location (transplants: January 2010–June 2018). CF, cystic fibrosis; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; OB, obliterative bronchiolitis; PH-not IPAH, pulmonary hypertension-not idiopathic pulmonary arterial hypertension; Retx, retransplantation.
Figure 4
Figure 4
Diagnosis distribution by era for pediatric lung transplants (transplants: January 1992–June 2018). CF, cystic fibrosis; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; OB, obliterative bronchiolitis; PH-not IPAH, pulmonary hypertension-not idiopathic pulmonary arterial hypertension; Retx, retransplant.
Figure 5
Figure 5
Induction immunosuppression use for pediatric lung transplants (transplants: January 2010–June 2018). ALG, anti-lymphocyte globulin; ATG, anti-thymocyte globulin; IL-2R, interleukin-2 receptor.
Figure 6
Figure 6
Kaplan-Meier survival conditional on survival to 1 year for pediatric and adult lung transplants (transplants: January 1992–June 2017).
Figure 7
Figure 7
Kaplan-Meier survival for pediatric lung transplants by era (transplants: January 1992–June 2017). NA, not applicable.
Figure 8
Figure 8
Kaplan-Meier survival for pediatric lung transplants by sex (transplants: January 1992–June 2017).
Figure 9
Figure 9
Kaplan-Meier survival for pediatric lung transplants by stages of chronic kidney disease at transplant (transplants: January 1992–June 2017). eGFR was calculated using the Schwartz formula. The stages of CKD are as follows: 1: eGFR ≥90; 2: eGFR = 60–89; 3: eGFR = 30–59. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; NS, not significant.
Figure 10
Figure 10
Kaplan-Meier survival for primary pediatric lung transplants and pediatric lung retransplants (transplants: January 2000–June 2017).
Figure 11
Figure 11
Hazard ratio of 10-year mortality/graft failure for pediatric lung transplants by donor age (transplants: 2000–June 2008).
Figure 12
Figure 12
Percentage of pediatric lung recipients experiencing any rejection between discharge and 1-year follow-up (follow-ups: January 2005–June 2018).
Figure 13
Figure 13
Freedom from bronchiolitis obliterans syndrome for lung transplants by age group (pediatric vs adult) (transplants: January 1995–June 2017).
Figure 14
Figure 14
Distribution of donor-recipient height difference for pediatric lung transplants by recipient age (transplants: January 2000–June 2018).
Figure 15
Figure 15
Kaplan-Meier freedom from BOS within 5 years for pediatric lung transplants by donor-recipient height difference (transplants: January 1995-June 2013). BOS, bronchiolitis obliterans syndrome; NS, not significant.
Figure 16
Figure 16
Kaplan-Meier survival within 1 year for pediatric lung transplants by donor-recipient height difference (transplants: January 1995–June 2017). NS, not significant.
Figure 17
Figure 17
Kaplan-Meier survival within 5 years for pediatric lung transplants by donor-recipient height difference (transplants: January 1995–June 2013). NS, not significant.
Figure 18
Figure 18
Volume of transplantation and recipient age distribution for pediatric heart-lung transplants (transplants: 1984–2017).
Figure 19
Figure 19
Kaplan-Meier survival for pediatric heart-lung transplants by major diagnosis (transplants: January 1992–June 2017). CF, cystic fibrosis; IPAH, idiopathic pulmonary arterial hypertension; NS, not significant; PH-not IPAH, pulmonary hypertension-not idiopathic pulmonary arterial hypertension.
Figure 20
Figure 20
Distribution of donor-recipient height difference for pediatric heart-lung transplants by recipient age (transplants: January 1992–June 2018).
Figure 21
Figure 21
Kaplan-Meier survival within 1 year for pediatric heart-lung transplants by donor-recipient height difference (transplants: January 1992–June 2017). NS, not significant.
Figure 22
Figure 22
Kaplan-Meier survival within 5 years for pediatric heart-lung transplants by donor-recipient height difference (transplants: January 1992–June 2013). NS, not significant.
See this image and copyright information in PMC

References

    1. Fraser CD 3rd, Zhou X, Grimm JC, et al. Size mismatching increases mortality following lung transplantation in preadolescent patients. Ann Thorac Surg 2019;108:130–7. - PubMed
    1. Eberlein M, Permutt S, Chahla MF, et al. Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndrome. Chest 2012;141: 451–60. - PMC - PubMed
    1. Eberlein M, Arnaoutakis GJ, Yarmus L, et al. The effect of lung size mismatch on complications and resource utilization after bilateral lung transplantation. J Heart Lung Transplant 2012;31:492500. - PubMed
    1. Eberlein M, Reed RM, Maidaa M, et al. Donor-recipient size matching and survival after lung transplantation. A cohort study. Ann Am Thorac Soc 2013;10:418–25. - PubMed
    1. Eberlein M, Reed RM, Bolukbas S, et al. Lung size mismatch and primary graft dysfunction after bilateral lung transplantation. J Heart Lung Transplant 2015;34:233–40. - PMC - PubMed